New cocktail targets rare breast cancer that defies standard treatment

NCT ID NCT05660083

Recruiting now Disease control Sponsor: The Methodist Hospital Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing a combination of three drugs—alpelisib, L-NMMA, and nab-paclitaxel—in people with a rare, aggressive form of breast cancer called metaplastic breast cancer (MpBC) that has spread or is locally advanced. The study aims to find the best dose and see if the combo can shrink tumors. About 36 adults whose cancer is HER2-negative and has not responded to prior treatments will participate.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: alpelisib, L-NMMA (iNOS inhibitor), and nab-paclitaxel
What this could lead to: If successful, this could offer a new treatment option for people with a rare and aggressive form of breast cancer that has not responded to standard therapies.
What could go wrong: This is a small, early-phase trial (36 people) testing a combination of drugs, so results may not apply widely. Side effects like high blood sugar, blood clots, and high blood pressure are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2-NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm Her2-receptor negative breast cancer metaplastic breast carcinoma triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HER2-NEGATIVE BREAST CANCER METAPLASTIC BREAST CARCINOMA METASTATIC BREAST CANCER TNBC - TRIPLE-NEGATIVE BREAST CANCER

Contacts and locations

Locations

Houston Methodist Neal Cancer Center
RECRUITING

Houston, Texas, 77030, United States
National Institute of Health Clinical Center
RECRUITING

Bethesda, Maryland, 20892, United States
The University of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.